-
Primary Prevention Trial Designs Using Coronary Imaging: A National Heart, Lung, and Blood Institute WorkshopP Greenland, ED Michos, N Redmond et al. -
Canagliflozin and Renal Outcomes in Type 2 Diabetes and NephropathyPerkovic V, Jardine MJ, CREDENCE Trial Investigators.
-
The Year in Cardiovascular Medicine 2020: Coronary Prevention: Looking back on the Year in Cardiovascular Medicine for 2020 in the field of coronary prevention is Professor Ramon Estruch, Dr Luis Ruilope, and Professor Francesco Cosentino. Mark Nicholls meets themM Nicholls.
-
The sinus venosus contributes to coronary vasculature through VEGFC-stimulated angiogenesisHI Chen , B Sharma, K Red-Horse et al.
-
High-Risk Coronary Plaque Regression After Intensive Lifestyle Intervention in Nonbstructive Coronary Disease: A Randomized StudyJ Henzel, C Kępka, M Kruk et al.
-
Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular DiseaseA Prespecified Analysis From the FOURIER TrialMurphy SA, Pedersen TR, Gaciong ZA et al.
-
Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-ITDL Bhatt, G Steg, and on behalf of the REDUCE-IT Investigators.
-
Value of Coronary Artery Calcium Scanning in Association With the Net Benefit of Aspirin in Primary Prevention of Atherosclerotic Cardiovascular DiseaseE Ajufo, CR Ayers, R Vigen et al.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
